LYME DISEASE MICROBIOLOGY

'Lyme disease', or 'borreliosisis', is caused by Gram negative spirochetal bacteria from the genus ''Borrelia'', which has at least 37 known species, 12 of which are Lyme related, and an unknown number of genomic strains. ''Borrelia'' species known to cause Lyme disease are collectively known as ''Borrelia burgdorferi'' sensu lato.
''Borrelia'' are microaerophillic and slow-growing—the primary reason for the long delays when diagnosing Lyme disease—and have been found to have greater strain diversity than previously estimated.^[1] The strains differ in clinical symptoms and/or presentation as well as geographic distribution. Sherris Medical Microbiology, Ryan KJ, Ray CG (editors), , , McGraw Hill, 2004,
Except for ''Borrelia recurrentis'' (which causes louse-borne relapsing fever and is transmitted by the human body louse), all known species are believed to be transmitted by ticks.^[2]

Contents

Species and Strains

Emerging Genospecies

B. lonestari

Epidemiology

Life cycle

Genomic characteristics

Outer Surface Proteins

Structure and growth

Mechanisms of persistence

Advancing Immunology Research

References

External links

Species and Strains

Until recently it was thought that only three genospecies caused Lyme disease (borreliosis): ''B. burgdorferi'' sensu stricto ( the predominant species in North America, but also present in Europe); ''B. afzelii''; and ''B. garinii'' (both predominant in Eurasia). To date the complete genome of ''B. burgdorferi'' sensu stricto strain B31, B. afzelii strain PKo and B. garinii strain PBi is known. ''B. burgdorferi'' strain B31 was derived by limited dilutional cloning from the original Lyme-disease tick isolate derived by Alan Barbour.
At present, diagnostic tests are based only on ''B. burgdorferi'' sensu stricto (the only species used in the U.S.), ''B. afzelii'', and ''B. garinii''.

Emerging Genospecies

★ ''B. valaisiana'' was identified as a genomic species from Strain VS116, and named B. valaisiana in 1997.^[3] It was later detected by Polymerase chain reaction (PCR) in human cerebral spinal fluid (CSF) in Greece.^[4] ''B. valaisiana'' has been isolated throughout Europe, as well east Asia.^[5]
Newly discovered genospecies have also been found to cause disease in humans:

★ ''B. lusitaniae'' ^[6] in Europe (especially Portugal), North Africa and Asia.

★ ''B. bissettii'' ^[7][8] in the U.S. and Europe.

★ ''B. spielmanii'' ^[9][10] in Europe.
Additional ''B. burgdorferi'' sensu lato genospecies suspected of causing illness, but not confirmed by culture, include B. japonica, B. tanukii and B. turdae (Japan); B. sinica (China); and ''B. andersonii'' (U.S.). Some of these species are carried by ticks not currently recognized as carriers of Lyme disease.
The ''B. miyamotoi'' spirochete, related to the relapsing fever group of spirochetes, is also suspected of causing illness in Japan. Spirochetes similar to B. miyamotoi have recently been found in both I. ricinus ticks in Sweden and I. scapularis ticks in the U.S.^[11][12]

B. lonestari

Apart from this group of closely related genospecies, additional Borrelia species of interest include B. lonestari, a spirochete recently detected in the Amblyomma americanum tick (Lone Star tick) in the U.S.^[13] ''B. lonestari'' is suspected of causing STARI (Southern Tick-Associated Rash Illness), also known as Masters disease in honor of its discoverer Ed Masters. The illness follows a Lone Star tick bite and clinically resembles Lyme disease, but sufferers usually test negative for Lyme.^[14]There is currently no diagnostic test available for STARI/Masters, and no official treatment protocol, though antibiotics are generally prescribed.

Epidemiology

The number of reported cases of the Lyme disease (borreliosis) have been increasing, as are endemic regions in North America. Of cases reported to the United States Center for Disease Control (CDC), the ratio of Lyme disease infection is 7.9 cases for every 100,000 persons. In the ten states where Lyme disease is most common, the average was 31.6 cases for every 100,000 persons for the year 2005.^[15] Although Lyme disease has now been reported in 49 of 50 states in the U.S, about 99% of all reported cases are confined to just five geographic areas (New England, Mid-Atlantic, East-North Central, South Atlantic, and West North-Central).^[16]
In Europe, cases of ''B. burgdorferi'' sensu lato infected ticks are found predominantly in Norway, Netherlands, Germany, France, Italy, Slovenia and Poland, but have been isolated in almost every country on the continent. Lyme disease statistics for Europe can be found at Eurosurveillance website.
Borrelia burgdoferi sensu lato infested ticks are being found more frequently in Japan, as well as in Northwest China and far eastern Russia.^[17][18] Borrelia has been isolated in Mongolia as well.^[19]
In South America tick borne disease recognition and occurrence is rising. Ticks carrying Borrelia burgdoferi sensu lato, as well as canine and human tick-borne disease, has been reported widely in Brazil, but the subspecies of borrelia has not yet been defined.^[20] The first reported case of Lyme Disease in Brazil was made in 1993 in Sao Paulo.^[21] Borrelia burgdorferi sensu stricto antigens in patients have been identified in Colombia and in Bolivia.
In Northern Africa Borrelia burgdoferi sensu lato has been identified in Morroco, Algeria, Egypt and Tunisia.^[22][23][24]
In Western and Sub-Saharan Africa, tick-borne relapsing fever has been recognized for over a century, first isolated by the British physicians Joseph Dutton and John Todd in 1905. Borrelia in the manifestation of Lyme disease in this region is presently unknown but evidence indicates that the disease may occur in humans in sub-Saharan Africa. The abundance of hosts and tick vectors would favor the establishment of the infection in Africa.^[25]In East Africa two cases of Lyme disease have been reported in Kenya.^[26]
In Australia there is no definitive evidence for the existence of ''B. burgdorferi'' or for any other tick-borne spirochete that may be responsible for a local syndrome being reported as Lyme disease.^[27] Cases of neuroborreliois have been documented in Australia but are often ascribed to travel to other continents. The existence of Lyme disease in Australia is controversial.
To date data shows that Northern hemisphere temperate regions are most endemic for Lyme disease.^[28][29]

Life cycle

The life-cycle of ''B. burgdorferi'' is complex, requiring ticks, rodents, and deer at various points. Mice are the primary reservoir for the bacteria; Ixodes ticks then transmit the ''B. burgdorferi'' infection to deer.
Hard ticks have a variety of life histories with respect to optimizing their chance of contact with an appropriate host to ensure survival. The life stages of soft ticks are not readily distinguishable. The first life stage to come out of the egg, a six legged larva, takes a blood meal from a host, and molts to the first nymphal stage. Unlike hard ticks, many soft ticks go through multiple nymphal stages, gradually increasing in size until the final molt to the adult stage.
The life cycle of the deer tick comprises three growth stages: the larva, nymph and adult.
The life-cycle concept encompassing reservoirs and infections in multiple hosts has recently been expanded to encompass forms of the spirochete which differ from the motile corkscrew form, and these include cystic forms spheroplast-like, straighted non-coiled bacillary forms which are immotile due to flagellin mutations and granular forms coccoid in profile. The model of Plasmodium species Malaria with multiple parasitic profiles demonstrable in various host insects and mammals is a hypothesized model for a similarly complex proposed Borrelia spirochete life cycle.
^[30]
[31]
Whereas B. burgdoferi is most associated with deer tick and the white footed mouse,^[32] B. afzelii is most frequently detected in rodent-feeding vector ticks, B.garinii and B. valaisiana appear to be associated with birds. Both rodents and birds are competent reservoir hosts for Borrelia burgdorferi sensu stricto. The resistance of a genospecies of Lyme disease spirochetes to the bacteriolytic activities of the alternative immune complement pathway of various host species may determine its reservoir host association.

Genomic characteristics

One of the most striking features of ''B. burgdorferi'' as compared with other eubacteria is its unusual genome, which is far more complex than that of its spirochetal cousin ''Treponema pallidum'', the agent of syphilis.^[33]
The genome of ''B. burgdorferi'' includes a linear chromosome approximately one megabase in size, with 21 plasmids (12 linear and 9 circular) - by far the largest number of plasmids found in any known bacterium.^[34]
Genetic exchange, including plasmid transfers, contributes to the pathogenicity of the organism.^[35]
Long-term culture of ''B. burgdorferi'' results in a loss of some plasmids and changes in expressed protein profiles. Associated with the loss of plasmids is a loss in the ability of the organism to infect laboratory animals, suggesting that the plasmids encode key genes involved in virulence.
Chemical analysis of the external membrane of ''B. burgdorferi'' revealed the presence of 46% proteins, 51% lipids and 3% carbohydrates.^[36]

Outer Surface Proteins

The outer membrane of Borrelia burgdorferi is composed of various unique outer surface proteins (Osp) that have been characterized (OspA through OspF). They are presumed to play a role in virulence.
OspA and OspB are by far the most abundant outer surface proteins.
The OspA and OspB genes encode the major outer membrane proteins of the B burgdorferi. The two Osp proteins show a high degree of sequence similarity, indicating a recent evolutionary event. Molecular analysis and sequence comparison of OspA and OspB with other proteins has revealed similarity to the signal peptides of prokaryotic lipoproteins.^[37]Virtually all spirochetes in the midgut of an unfed nymph tick express OspA.
OspC is an antigen-detection of its presence by the host organism and can stimulate an immune response. While each individual bacterial cell contains just one copy of the gene encoding OspC, populations of ''B. burgdorferi'' have shown high levels of variation among individuals in the gene sequence for OspC.^[38] OspC is likely to play a role in transmission from vector to host, since it has been observed that the protein is only expressed in the presence of mammalian blood or tissue. Fikrig, E. and Pal, U. Adaptation of Borrelia burgdorferi in the vector and vertebrate host. Microbes and Infection Volume 5, Issue 7, June 2003, Pages 659-666. PMID 12787742
The functions of OspD are unknown.
OspE and OspF are structurally arranged in tandem as one transcriptional unit under the control of a common promoter.^[39]
In transmission to the mammaliam host, when the nymphal tick begins to feed, and the spirochetes in the midgut begin to multiply rapidly, most spirochetes cease expressing OspA on their surface. Simultaneous with the disappearance of OspA, the spirochete population in the midgut begins to express a OspC. Upregulation of OspC begins during the first day of feeding and peaks 48 hours after attachment.^[40]

Structure and growth

''B. burgdorferi'' is a highly specialized, motile, two-membrane, spiral-shaped spirochete ranging from about 9 to 32 micrometers in length. It is often described as gram-negative and has an outer membrane with lipopolysaccharide (LPS), though it stains only weakly in the Gram stain. ''B. burgdorferi'' is a microaerophilic organism, requiring little oxygen to survive. It lives primarily as an extracellular pathogen, although it can also hide intracellularly (see Mechanisms of persistence section).
Like other spirochetes such as T. pallidum (the agent of syphilis), ''B. burgdorferi'' has an axial filament composed of flagella which run lengthways between its cell wall and outer membrane. This structure allows the spirochete to move efficiently in corkscrew fashion through viscous media, such as connective tissue. As a result, ''B. burgdorferi'' can disseminate throughout the body within days to weeks of infection, penetrating deeply into tissue where the immune system and antibiotics may not be able to eradicate the infection.
''B. burgdorferi'' is very slow growing, with a doubling time of 12-18 hours^[41] (in contrast to pathogens such as Streptococcus and Staphylococcus, which have a doubling time of 20-30 minutes). Since most antibiotics kill bacteria only when they are dividing, this longer doubling time necessitates the use of relatively longer treatment courses for Lyme disease. Antibiotics are most effective during the growth phase, which for ''B. burgdorferi'' occurs in four-week cycles.

Mechanisms of persistence

While ''B. burgdorferi'' is susceptible to a number of antibiotics in vitro, there are contradictory reports as to the efficacy of antibiotics in vivo. ''B. burgdorferi'' may persist in humans and animals for months or years despite a robust immune response and standard antibiotic treatment, particularly when treatment is delayed and dissemination widespread. Numerous studies have demonstrated persistence of infection despite antibiotic therapy.^[42][43][44]
Various survival strategies of ''B. burgdorferi'' have been posited to explain this phenomenon,^[45] including the following:

★ Physical sequestration of ''B. burgdorferi'' in sites that are inaccessible to the immune system and antibiotics, such as the brain^[46] and central nervous system. New evidence suggests that ''B. burgdorferi'' may use the host's fibrinolytic system to penetrate the blood-brain barrier.^[47]

★ Intracellular invasion.
''B. burgdorferi'' has been shown to invade a variety of cells, including endothelium,^[48] fibroblasts,^[49] lymphocytes,^[50] macrophages,^[51] keratinocytes,^[52] synovium,^[53][54] and most recently neuronal and glial cells. ^[55] By 'hiding' inside these cells, ''B. burgdorferi'' is able to evade the immune system and is protected to varying degrees against antibiotics,^[56][57] allowing the infection to persist in a chronic state.

★ Altered morphological forms, i.e. spheroplasts (cysts, granules).
The existence of ''B. burgdorferi'' spheroplasts, which lack a cell wall, has been documented in vitro,^{[58][59][60][61]} in vivo,^5459[62] and in an ex vivo model.^[63] The fact that energy is required for the spiral bacterium to convert to the cystic form⁵⁸ suggests that these altered forms have a survival function, and are not merely end stage degeneration products. The spheroplasts are indeed virulent and infectious, able to survive under adverse environmental conditions, and have been shown to revert back to the spiral form in vitro, once conditions are more favorable.^[64][65]
A number of other factors make ''B. burgdorferi'' spheroplasts a key factor in the relapsing, chronic nature of Lyme disease. Compared to the spiral form, spheroplasts have dramatically reduced surface area for immune surveillance. They also express different surface proteins - another reason for seronegative disease (i.e. false-negative antibody tests), as current tests only look for antibodies to surface proteins of the ''spiral'' form. In addition, ''B. burgdorferi'' spheroplasts are generally not susceptible to the antibiotics traditionally used for Lyme disease. They have instead shown sensitivity in vitro to antiparasitic drugs such as metronidazole, ^[66] tinidazole, ^[67] and hydroxychloroquine, ^[68] to which the spiral form of ''B. burgdorferi'' is not sensitive.

★ Antigenic variation and gene expression.
Like the Borrelia that cause relapsing fever, ''B. burgdorferi'' has the ability to vary its surface proteins in response to immune attack.^45[69] This ability is related to the genomic complexity of ''B. burgdorferi'', and is another way ''B. burgdorferi'' evades the immune system to establish a chronic infection.^[70]

★ Immune system suppression.
Complement inhibition, induction of anti-inflammatory cytokines such as IL-10, and the formation of immune complexes have all been documented in ''B. burgdorferi'' infection.⁴⁵ Furthermore, the existence of immune complexes provides another explanation for seronegative disease (i.e. false-negative antibody tests of blood and cerebrospinal fluid), as studies have shown that substantial numbers of seronegative Lyme patients have antibodies bound up in these complexes.^[71]

Advancing Immunology Research

The role of T cells in borrelia was first made in 1984,^[72] the role of cellular immunity in active Lyme disease was made in 1986,^[73] and long term persistance of T cell lymphocyte responses to ''B. burgdorferi'' as an "immunological scar syndrome" was hypothesized in 1990.^[74] The role Th1 and interferon-gamma (INF-gamma) in borrelia was first described in 1995.^[75] The cytokine pattern of Lyme disease, and the role of Th1 with down regulation of interleukin-10 (IL-10) was first proposed in 1997.^[76]
Recent studies in both acute and antibiotic refractory, or chronic, Lyme disease have shown a distinct pro-inflammatory immune process. This pro-inflammatory process is a cell-mediated immunity and results in Th1 upregulation. These studies have shown a significant decrease in cytokine output of (IL-10), an upregulation of Interleukin-6 (IL-6) and Interleukin-12 (Il-12) and Interferon-gamma (IFN-gamma) and disregulation in TNF-alpha predominantly.
New research has also found that chronic Lyme patients have higher amounts of Borrelia-specific forkhead box P3 (FoxP3) than healthy controls, indicating that regulatory T cells might also play a role, by immunosuppression, in the development of chronic Lyme disease. FoxP3 are a specific marker of regulatory T cells.^[77] The signaling pathway P38 mitogen-activated protein kinases (p38 MAP kinase) has also been identified as promoting expression of proinflammatory cytokines from borrelia.^[78][79]
The culmination of these new and ongoing immunological studies suggest this cell-mediated immune disruption in the Lyme patient amplifies the inflammatory process, often rendering it chronic and self-perpetuating, regardless of whether the borrelia bacterium is still present in the host, or in the absence of the inciting pathogen in an autoimmune pattern.^[80]

References

1. Sequence typing reveals extensive strain diversity of the Lyme borreliosis agents Borrelia burgdorferi in North America and Borrelia afzelii in Europe, Bunikis J, Garpmo U, Tsao J, Berglund J, Fish D, Barbour AG, , , Microbiology, 2004
2. Borrelia: Strains, Vectors, Human and Animal Borreliosis, Felsenfeld O, , , Warren H. Green, Inc, 1971,
3. Genetic and phenotypic analysis of Borrelia valaisiana sp. nov. (Borrelia genomic groups VS116 and M19), Wang G, van Dam AP, Le Fleche A, ''et al'', , , Int. J. Syst. Bacteriol., 1997
4. Borrelia valaisiana in cerebrospinal fluid, Diza E, Papa A, Vezyri E, Tsounis S, Milonas I, Antoniadis A, , , Emerging Infect. Dis., 2004
5. Terrestrial distribution of the Lyme borreliosis agent Borrelia burgdorferi sensu lato in East Asia, Masuzawa T, , , Jpn. J. Infect. Dis., 2004
6. First isolation of Borrelia lusitaniae from a human patient, Collares-Pereira M, Couceiro S, Franca I, Kurtenbach K, Schafer SM, Vitorino L, Goncalves L, Baptista S, Vieira ML, Cunha C, , , J Clin Microbiol, 2004
7. Expanded diversity among Californian borrelia isolates and description of Borrelia bissettii sp. nov. (formerly Borrelia group DN127), Postic D, Ras NM, Lane RS, Hendson M, Baranton G, , , J Clin Microbiol, 1998
8. Solitary borrelial lymphocytoma in adult patients, Maraspin V, Cimperman J, Lotric-Furlan S, Ruzic-Sabljic E, Jurca T, Picken RN, Strle F, , , Wien Klin Wochenschr, 2002
9. Delineation of Borrelia burgdorferi sensu lato species by multilocus sequence analysis and confirmation of the delineation of Borrelia spielmanii sp. nov, Richter D, Postic D, Sertour N, Livey I, Matuschka FR, Baranton G, , , Int J Syst Evol Microbiol, 2006
10. Borrelia spielmanii erythema migrans, Hungary, Foldvari G, Farkas R, Lakos A, , , Emerg Infect Dis, 2005
11. A relapsing fever group spirochete transmitted by Ixodes scapularis ticks, Scoles GA, Papero M, Beati L, Fish D, , , Vector Borne Zoonotic Dis, 2001
12. Typing of Borrelia relapsing fever group strains, Bunikis J, Tsao J, Garpmo U, Berglund J, Fish D, Barbour AG, , , Emerg Infect Dis, 2004
13. First culture isolation of Borrelia lonestari, putative agent of southern tick-associated rash illness, Varela AS, Luttrell MP, Howerth EW, Moore VA, Davidson WR, Stallknecht DE, Little SE, , , J Clin Microbiol, 2004
14. Physician-diagnosed erythema migrans and erythema migrans-like rashes following Lone Star tick bites, Masters E, Granter S, Duray P, Cordes P, , , Arch Dermatol, 1998
15. DVBID: Disease Upward Climb - CDC Lyme Disease
16. Lyme Disease Statistics
17. Li M, Masuzawa T, Takada N, Ishiguro F, Fujita H, Iwaki A, Wang H, Wang J, Kawabata M, Yanagihara Y. "Lyme disease Borrelia species in northeastern China resemble those isolated from far eastern Russia and Japan". Appl Environ Microbiol 1998 Jul;64(7):2705-9
18. Masuzawa T. "Terrestrial distribution of the Lyme borreliosis agent Borrelia burgdorferi sensu lato in East Asia".Jpn J Infect Dis. 2004 Dec;57(6):229-35
19. Walder G, Lkhamsuren E, Shagdar A, Bataa J, Batmunkh T, Orth D, Heinz FX, Danichova GA, Khasnatinov MA, Wurzner R, Dierich MP."Serological evidence for tick-borne encephalitis, borreliosis, and human granulocytic anaplasmosis in Mongolia."Int J Med Microbiol. 2006 May;296 Suppl 40:69-75.
20. Mantovani E, Costa IP, Gauditano G, Bonoldi VL, Higuchi ML, Yoshinari NH."Description of Lyme disease-like syndrome in Brazil: is it a new tick borne disease or Lyme disease variation?" Braz J Med Biol Res. 2007 Apr;40(4):443-56.
21. Yoshinari NH, Oyafuso LK, Monteiro FG, de Barros PJ, da Cruz FC, Ferreira LG, Bonasser F, Baggio D, Cossermelli W."Lyme disease. Report of a case observed in Brazil" Rev Hosp Clin Fac Med Sao Paulo. 1993 Jul-Aug;48(4):170-4.
22. Bouattour A, Ghorbel A, Chabchoub A, Postic D. "Lyme borreliosis situation in North Africa" Arch Inst Pasteur Tunis. 2004;81(1-4):13-20
23. Dsouli N, Younsi-Kabachii H, Postic D, Nouira S, Gern L, Bouattour A. "Reservoir role of lizard Psammodromus algirus in transmission cycle of Borrelia burgdorferi sensu lato (Spirochaetaceae) in Tunisia." J Med Entomol. 2006 Jul;43(4):737-42.
24. Helmy N. "Seasonal abundance of Ornithodoros (O.) savignyi and prevalence of infection with Borrelia spirochetes in Egypt". J Egypt Soc Parasitol. 2000 Aug;30(2):607-19.
25. Fivaz BH, Petney TN. "Lyme disease--a new disease in southern Africa?"
J S Afr Vet Assoc. 1989 Sep;60(3):155-8.
26. Jowi JO, Gathua SN. Lyme disease: report of two cases. East Afr Med J. 2005 May;82(5):267-9.
PMID 16119758
27. Piesman J, Stone BF. Vector competence of the Australian paralysis tick, Ixodes holocyclus, for the Lyme disease spirochete Borrelia burgdorferi. Int J Parasitol. 1991 Feb;21(1):109-11.PMID 2040556
28. Grubhoffer L, Golovchenko M, Vancova M, Zacharovova-Slavickova K, Rudenko N, Oliver JH Jr. Lyme borreliosis: insights into tick-/host-borrelia relations. Folia Parasitol (Praha). 2005 Nov;52(4):279-94. Review. PMID 16405291
29. Higgins R. Emerging or re-emerging bacterial zoonotic diseases: bartonellosis, leptospirosis, Lyme borreliosis, plague. Rev Sci Tech. 2004 Aug;23(2):569-81.PMID 15702720
30. Macdonald AB. "A life cycle for Borrelia spirochetes?" Med Hypotheses. 2006;67(4):810-8. PMID 16716532
31. Lymeinfo.net - LDAdverseConditions
32. Wallis RC, Brown SE, Kloter KO, Main AJ Jr. Erythema chronicum migrans and lyme arthritis: field study of ticks. Am J Epidemiol. 1978 Oct;108(4):322-7.PMID 727201
33. Borrelia burgdorferi and Treponema pallidum: a comparison of functional genomics, environmental adaptations, and pathogenic mechanisms, Porcella SF, Schwan TG, , , J Clin Invest, 2001
34. A bacterial genome in flux: the twelve linear and nine circular extrachromosomal DNAs in an infectious isolate of the Lyme disease spirochete Borrelia burgdorferi, Casjens S, Palmer N, van Vugt R, Huang WM, Stevenson B, Rosa P, Lathigra R, Sutton G, Peterson J, Dodson RJ, Haft D, Hickey E, Gwinn M, White O, Fraser CM, , , Mol Microbiol, 2000
35. Genetic exchange and plasmid transfers in Borrelia burgdorferi sensu stricto revealed by three-way genome comparisons and multilocus sequence typing, Qiu WG, Schutzer SE, Bruno JF, Attie O, Xu Y, Dunn JJ, Fraser CM, Casjens SR, Luft BJ, , , Proc Natl Acad Sci U S A, 2004
36. K. "Lyme borreliosis: review of present knowledge"
Cesk Epidemiol Mikrobiol Imunol. 1993 Jun;42(2):87-92.
37. Bergstrom S. , Bundoc V.G. , Barbour A.G. Molecular analysis of linear plasmid-encoded major surface proteins, OspA and OspB, of the Lyme disease spirochaete Borrelia burgdorferi. Mol. Microbiol. 3 479-486 1989
38. Girschick, J. and Singh, S.E. Molecular survival strategies of the lyme disease spirochete Borrelia burgdorferi. Sep, 2004. The Lancet Infectious Diseases: Volume 4, Issue 9, September 2004, Pages 575-583.
39. Lam TT, Nguyen TP, Montgomery RR, Kantor FS, Fikrig E, Flavell RA. Outer surface proteins E and F of Borrelia burgdorferi, the agent of Lyme disease. Infect Immun. 1994 Jan;62(1):290-8.
40. Schwan TG, Piesman J. Temporal changes in outer surface proteins A and C of the Lyme disease-associated spirochete, Borrelia burgdorferi, during the chain of infection in ticks and mice. J Clin Microbiol 2000;38:382-8.
41. Kelly, R. T. (1984). Genus IV. Borrelia Swellengrebel 1907, 582AL. In Bergey's Manual of Systematic Bacteriology, vol. 1, pp. 57–62. Edited by N. R. Krieg & J. G. Holt. Baltimore: Williams & Wilkins.
42. Borrelia burgdorferi DNA in the urine of treated patients with chronic Lyme disease symptoms. A PCR study of 97 cases, Bayer ME, Zhang L, Bayer MH, , , Infection, 1996
43. Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis, Preac-Mursic V, Weber K, Pfister HW, ''et al'', , , Infection, 1989
44. Borrelia burgdorferi detected by culture and PCR in clinical relapse of disseminated Lyme borreliosis, Oksi J, Marjamaki M, Nikoskelainen J, Viljanen MK, , , Ann Med, 1999
45. Survival strategies of Borrelia burgdorferi, the etiologic agent of Lyme disease, Embers ME, Ramamoorthy R, Philipp MT, , , Microbes Infect, 2004
46. Borrelia burgdorferi persists in the brain in chronic lyme neuroborreliosis and may be associated with Alzheimer disease, Miklossy J, Khalili K, Gern L, ''et al'', , , J Alzheimers Dis, 2004
47. Borrelia burgdorferi, host-derived proteases, and the blood-brain barrier, Grab DJ, Perides G, Dumler JS, Kim KJ, Park J, Kim YV, Nikolskaia O, Choi KS, Stins MF, Kim KS, , , Infect Immun, 2005
48. Intracellular localization of Borrelia burgdorferi within human endothelial cells, Ma Y, Sturrock A, Weis JJ, , , Infect Immun, 1991
49. Invasion of human skin fibroblasts by the Lyme disease spirochete, Borrelia burgdorferi, Klempner MS, Noring R, Rogers RA, , , J Infect Dis, 1993
50. Invasion and cytopathic killing of human lymphocytes by spirochetes causing Lyme disease, Dorward DW, Fischer ER, Brooks DM, , , Clin Infect Dis, 1997
51. The fate of Borrelia burgdorferi, the agent for Lyme disease, in mouse macrophages. Destruction, survival, recovery, Montgomery RR, Nathanson MH, Malawista SE, , , J Immunol, 1993
52. Heterogeneity of Borrelia burgdorferi in the skin, Aberer E, Kersten A, Klade H, Poitschek C, Jurecka W, , , Am J Dermatopathol, 1996
53. Intracellular persistence of Borrelia burgdorferi in human synovial cells, Girschick HJ, Huppertz HI, Russmann H, Krenn V, Karch H, , , Rheumatol Int, 1996
54. Ultrastructural demonstration of spirochetal antigens in synovial fluid and synovial membrane in chronic Lyme disease: possible factors contributing to persistence of organisms, Nanagara R, Duray PH, Schumacher HR Jr, , , Hum Pathol, 1996
55. Invasion of human neuronal and glial cells by an infectious strain of Borrelia burgdorferi., Livengood JA, Gilmore RD, , , Microbes Infect, 2006
56. Fibroblasts protect the Lyme disease spirochete, Borrelia burgdorferi, from ceftriaxone ''in vitro'', Georgilis K, Peacocke M, Klempner MS, , , J Infect Dis, 1992
57. Eucaryotic cells protect Borrelia burgdorferi from the action of penicillin and ceftriaxone but not from the action of doxycycline and erythromycin, Brouqui P, Badiaga S, Raoult D, , , Antimicrob Agents Chemother, 1996
58. Serum-starvation-induced changes in protein synthesis and morphology of Borrelia burgdorferi, Alban PS, Johnson PW, Nelson DR, , , Microbiology, 2000
59. Formation and cultivation of Borrelia burgdorferi spheroplast-L-form variants, Mursic VP, Wanner G, Reinhardt S, ''et al'', , , Infection, 1996
60. Effects of penicillin, ceftriaxone, and doxycycline on morphology of Borrelia burgdorferi, Kersten A, Poitschek C, Rauch S, Aberer E, , , Antimicrob Agents Chemother, 1995
61. Ultrastructure of Borrelia burgdorferi after exposure to benzylpenicillin, Schaller M, Neubert U, , , Infection, 1994
62. A proposal for the reliable culture of Borrelia burgdorferi from patients with chronic Lyme disease, even from those previously aggressively treated, Phillips SE, Mattman LH, Hulinska D, Moayad H, , , Infection, 1998
63. Invasion of human tissue ex vivo by Borrelia burgdorferi, Duray PH, Yin SR, Ito Y, ''et al'', , , J Infect Dis, 2005
64. Conversion of Borrelia garinii cystic forms to motile spirochetes ''in vivo'', Gruntar I, Malovrh T, Murgia R, Cinco M, , , APMIS, 2001
65. Induction of cystic forms by different stress conditions in Borrelia burgdorferi, Murgia R, Cinco M, , , APMIS, 2004
66. An ''in vitro'' study of the susceptibility of mobile and cystic forms of Borrelia burgdorferi to metronidazole, Brorson O, Brorson SH, , , APMIS, 1999
67. An ''in vitro'' study of the susceptibility of mobile and cystic forms of Borrelia burgdorferi to tinidazole, Brorson O, Brorson SH, , , Int Microbiol, 2004
68. An ''in vitro'' study of the susceptibility of mobile and cystic forms of Borrelia burgdorferi to hydroxychloroquine, Brorson O, Brorson SH, , , Int Microbiol, 2002
69. Borrelia burgdorferi changes its surface antigenic expression in response to host immune responses, Liang FT, Yan J, Mbow ML, ''et al'', , , Infect Immun, 2004
70. Temporal expression analysis of the Borrelia burgdorferi paralogous gene family 54 genes BBA64, BBA65, and BBA66 during persistent infection in mice, Gilmore RD, Howison RR, Schmit VL, ''et al'', , , Infect. Immun., 2007
71. Borrelia burgdorferi-specific immune complexes in acute Lyme disease, Schutzer SE, Coyle PK, Reid P, Holland B, , , JAMA, 1999
72. Newman K Jr, Johnson RC."T-cell-independent elimination of Borrelia turicatae".Infect Immun. 1984 Sep;45(3):572-6.
73. Dattwyler RJ, Thomas JA, Benach JL, Golightly MG."Cellular immune response in Lyme disease: the response to mitogens, live Borrelia burgdorferi, NK cell function and lymphocyte subsets". Zentralbl Bakteriol Mikrobiol Hyg [A]. 1986 Dec;263(1-2):151-9
74. Kruger H, Pulz M, Martin R, Sticht-Groh V. "Long-term persistence of specific T- and B-lymphocyte responses to Borrelia burgdorferi following untreated neuroborreliosis".
Infection. 1990 Sep-Oct;18(5):263-7.
75. Forsberg P, Ernerudh J, Ekerfelt C, Roberg M, Vrethem M, Bergstrom S. "The outer surface proteins of Lyme disease borrelia spirochetes stimulate T cells to secrete interferon-gamma (IFN-gamma): diagnostic and pathogenic implications".
Clin Exp Immunol. 1995 Sep;101(3):453-60.
76. Yin Z, Braun J, Neure L, Wu P, Eggens U, Krause A, Kamradt T, Sieper J. "T cell cytokine pattern in the joints of patients with Lyme arthritis and its regulation by cytokines and anticytokines". Arthritis Rheum. 1997 Jan;40(1):69-79.
77. Jarefors S, Janefjord CK, Forsberg P, Jenmalm MC, Ekerfelt C. "Decreased up-regulation of the interleukin-12Rbeta2-chain and interferon-gamma secretion and increased number of forkhead box P3-expressing cells in patients with a history of chronic Lyme borreliosis compared with asymptomatic Borrelia-exposed individuals." Clin Exp Immunol. 2007 Jan;147(1):18-27
78. Olson CM, Hedrick MN, Izadi H, Bates TC, Olivera ER, Anguita J. "p38 mitogen-activated protein kinase controls NF-kappaB transcriptional activation and tumor necrosis factor alpha production through RelA phosphorylation mediated by mitogen- and stress-activated protein kinase 1 in response to Borrelia burgdorferi antigens." Infect Immun. 2007 Jan;75(1):270-7. Epub 2006 Oct 30.
79. Ramesh G, Philipp MT. "Pathogenesis of Lyme neuroborreliosis: mitogen-activated protein kinases Erk1, Erk2, and p38 in the response of astrocytes to Borrelia burgdorferi lipoproteins". Neurosci Lett. 2005 Aug 12-19;384(1-2):112-6
80. Toll-like receptors in Borrelia burgdorferi-induced inflammation, Singh SK, Girschick HJ, , , Clin. Microbiol. Infect., 2006

External links

★ Atlas of Borrelia (images of spirochetal, spheroplast and granular forms)

★ NCBI Taxonomy Browser - Borrelia

★ Borrelia burgdoferi B31 Genome Page

★ Borrelia Garinii PBi Genome Page

★ Borrelia Afzelli PKo Gemonme Page

★ CDC - Vector Interactions and Molecular Adaptations of Lyme Disease and Relapsing Fever Spirochetes Associated with Transmission by Ticks